-
Mashup Score: 0ASCO24Home - 3 hour(s) ago
Supported by an independent educational grant from Genmab US, Inc. and AbbVie Join us for a symposium on bispecific antibodies for relapsed-refractory diffuse large B-cell lymphoma designed to encourage the exchange of ideas between leaders in the field and attendees. Experts will discuss clinical trial data, adverse event management, and current treatment approaches. This program will include a dynamic panel discussion and rapid-fire Q & A as well as an interactive audience Q & A. Section Chief,
Source: events.medscapelive.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0ASCO24Home - 16 hour(s) ago
Supported by an independent educational grant from Genmab US, Inc. and AbbVie This live roundtable discussion will center on the advancing field of bispecific antibodies in relapsed/refractory follicular lymphoma (R/R FL). This program will include a dynamic rapid-fire Q & A format. Experts in the field of follicular lymphoma will discuss clinical trial data, adverse event management, the current treatment landscape, and key differences between approved and emerging bispecific antibodies. Register Now
Source: events.medscapelive.orgCategories: General Medicine News, DermatologyTweet-
Master the latest on bispecific antibodies for R/R FL 🧬. Join @JoshuaBrodyMD, @lymphomaphilia, & @gilles_salles to learn how to differentiate therapies 💉, manage AEs, & integrate new data into care. Boost confidence in treatment strategies 🔬 https://t.co/7YWvqzb2Vm #ASCO24 https://t.co/cr3oy7bCWx
-
-
Mashup Score: 0ASCO24Home - 16 hour(s) ago
Supported by an independent educational grant from Genmab US, Inc. and AbbVie This live roundtable discussion will center on the advancing field of bispecific antibodies in relapsed/refractory follicular lymphoma (R/R FL). This program will include a dynamic rapid-fire Q & A format. Experts in the field of follicular lymphoma will discuss clinical trial data, adverse event management, the current treatment landscape, and key differences between approved and emerging bispecific antibodies. Register Now
Source: events.medscapelive.orgCategories: General Medicine News, Onc News and JournalsTweet-
Master the latest on bispecific antibodies for R/R FL 🧬. Join JoshuaBrodyMD, lymphomaphilia, & gilles_salles to learn how to differentiate therapies 💉, manage AEs, & integrate new data into care. Boost confidence in treatment strategies 🔬 https://t.co/JmEVfV78Mj #ASCO24 https://t.co/i8srPosAdg
-
-
Mashup Score: 398ACC24Transcatheter or Surgical Treatment of Aortic-Valve Stenosis | NEJM - 18 hour(s) ago
Among low-risk patients with severe, symptomatic aortic stenosis who are eligible for both transcatheter aortic-valve implantation (TAVI) and surgical aortic-valve replacement (SAVR), data are lack…
Source: www.nejm.orgCategories: General Medicine News, General Journals & SocietTweet
-
Mashup Score: 63ACC24Shooting the Messenger to Treat Hypertriglyceridemia | NEJM - 20 hour(s) ago
This editorial describes the science behind an antisense drug targeting APOC3 mRNA to treat hypertriglyceridemia.
Source: www.nejm.orgCategories: General Medicine News, General HCPsTweet
Dive into R/R DLBCL treatment with bispecific antibodies 🧬. Join LNastoupilMD & falchi_lorenzo to gain skills in selecting therapies, managing AEs, & using the latest data for optimal safety. Enhance your confidence & treatment strategies 💉🔬 https://t.co/uNdhRxiqq7 #ASCO24 https://t.co/pWeEKNs8cf